.

Deeper Knowledge, Faster

  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Queensland Health
Moodys
Teva
US Department of Justice
Covington
Johnson and Johnson
Dow
Federal Trade Commission
Cipla

Generated: June 28, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,932,273

« Back to Dashboard

Which drugs does patent 7,932,273 protect, and when does it expire?


Patent 7,932,273 protects PRADAXA and is included in one NDA. There have been two Paragraph IV challenges on Pradaxa.

This patent has fifty-eight patent family members in thirty-four countries.

Summary for Patent: 7,932,273

Title:3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino- ]propionic acid ethylester methansulfonate and its use as a medicament
Abstract: Ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-m- ethyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate in the crystalline modifications I and II and as the hemihydrate and the use thereof as a pharmaceutical composition.
Inventor(s): Schmid; Rolf (Baltringen, DE), Sieger; Peter (Mittelbiberach, DE), Sobotta; Rainer (Ingelheim am Rhein, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim, DE)
Application Number:12/022,655
Patent Claim Types:
see list of patent claims
Compound; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Boehringer Ingelheim
PRADAXA
dabigatran etexilate mesylate
CAPSULE;ORAL022512-001Oct 19, 2010RXYesNo7,932,273► SubscribeYY
Boehringer Ingelheim
PRADAXA
dabigatran etexilate mesylate
CAPSULE;ORAL022512-003Nov 20, 2015RXYesNo7,932,273► SubscribeYY
Boehringer Ingelheim
PRADAXA
dabigatran etexilate mesylate
CAPSULE;ORAL022512-002Oct 19, 2010RXYesYes7,932,273► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,932,273

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany103 39 862Aug 29, 2003

International Patent Family for Patent: 7,932,273

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Serbia53370► Subscribe
Portugal2060569► Subscribe
Portugal1660482► Subscribe
Peru03482005► Subscribe
New Zealand578586► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Baxter
Cipla
Cerilliant
Fish and Richardson
Covington
Accenture
Merck
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot